Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046806 · ClinicalTrials.gov registry record · Phase 1
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
A Phase 1 study of Hereditary Angioedema (HAE) and Angioedema, sponsored by Institute for Asthma and Allergy.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07046806 is a Phase 1 study of Hereditary Angioedema (HAE) and Angioedema that is actively recruiting participants, run by Institute for Asthma and Allergy. The registered enrollment target is 10 participants, below the 66-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07046806, a Phase 1 study of Hereditary Angioedema (HAE) and Angioedema, is actively recruiting participants, sponsored by Institute for Asthma and Allergy.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Conditions Studied
Interventions
- DRUG Deucrictibant XR tablet
- DRUG Placebo comparator to XR tablet
- DRUG Deucrictibant 20 mg capsule
- DRUG Placebo comparator to 20 mg capsule
Study Locations (1)
Maryland
- Institute For Asthma & Allergy - Wheaton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07046806
The ClinicalTrials.gov registry entry for NCT07046806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (85% lower). The listed sponsor is Institute for Asthma and Allergy, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 4 interventions - of which Deucrictibant XR tablet is the first listed.
NCT07046806 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07046806 about?
NCT07046806 is a clinical study titled "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients". To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute a...
What is the current status of trial NCT07046806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-03-10. Estimated completion is 2026-04-01.
What conditions does trial NCT07046806 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency.
What interventions are being tested in trial NCT07046806?
The interventions under investigation include: Deucrictibant XR tablet (DRUG), Placebo comparator to XR tablet (DRUG), Deucrictibant 20 mg capsule (DRUG), Placebo comparator to 20 mg capsule (DRUG).
Who is sponsoring clinical trial NCT07046806?
This trial is sponsored by Institute for Asthma and Allergy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07046806 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.